Ascentage Pharma Announces Nine Abstracts To Be Presented at the 2019 American Association for Cancer Research Annual Meeting

ROCKVILLE, MD and HONG KONG, CHINA— March 26th, 2019—Ascentage Pharma, globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases s, today announced that research results of its pipeline of small molecule therapeutics will be presented at the 2019 American Association for Cancer Research (AACR) annual meeting in Atlanta, March 29-April 3, 2019. AACR abstracts include: Title: Predicting Drug Sensitivity to A Novel BCL-2 and BCL-xL Dual Inhibitor In Solid Tumor PDX Trials Session Title: BCL-2 Family Proteins Session Date and Time: Monday, April 1, 2019 1:00 PM – 5:00 PM CDT Poster Number: 2503 Title: MDM2 Inhibitor APG-115 Synergizes With CDK4/6 Inhibitors In A Patient Derived Xenograft Model of Dedifferentiated Liposarcoma Session Title: Credentialing of Molecular Targets Session Date and Time: Monday, April 1, 2019 8:00 AM – 12:00 PM CDT Poster Number: 1253 Title: Activation of P53 In the Tumor Microenvironment by MDM2 Inhibitor APG-115 Synergizes With PD-1 Blockade Independently of P53 Status of Tumor Cells Session Title: Combination Immunotherapies 2 Session Date and Time: Tuesday, April 2, 2019 8:00 AM – 12:00 PM CDT Poster Number: 3192 Title: BCL-2 Selective Inhibitor APG-2575 Synergizes with BTK Inhibitor in Preclinical Xenograft Models of Follicular Lymphoma and diffuse Large B-cell Lymphoma Session Title: Apoptosis, Necrosis, and Cancer Cell Survival Session Date and Time: Monday, April 1, 2019 1:00 PM – 5:00 PM CDT Poster Number: 2058 Title: Synergistic Effect of BCL-2 Inhibitor APG-2575 and CDK9 Inhibitor in Acute Myeloid Leukemia and DLBCL Preclinical Tumor Models Session Title: Novel Antitumor Agents 1 Session Date and Time: Tuesday, April 2, 2019 8:00 AM – 12:00 PM CDT Poster Number: 3068 Title: FAK Blockade Enhances Antitumor Effect of BTK Inhibitor In Esophageal Squamous Cell Carcinoma via EGFR-ERK-Akt Pathway Inhibition Session Title: Combination Approaches to Novel Therapies Session Date and Time: Sunday, March 31, 2019 1:00 PM – 5:00 PM CDT Poster Number: 309 Title: A Novel Bcl-2/Bcl-XL Inhibitor APG-1252-12A as A Potential Therapeutic Strategy for Gastric Carcinoma Session Title: Apoptosis, Necrosis, and Cancer Cell Survival Session Date and Time: Monday, April 1, 2019 1:00 PM – 5:00 PM CDT Poster Number:2054 Title: FAK Inhibition Reduces Tumor Infiltration of Tregs Via Restricting CCL5 Release and Boosts the Present Therapeutic Regimen for BRAFV600E -mutated Colorectal Carcinoma Session Title: Immunomodulation by Chemotherapy and Targeted Agents Session Date and Time: Tuesday, April 2, 2019 1:00 PM – 5:00 PM CDT Poster Number: 3958 Title: Novel FAK/ALK/ROS1 Inhibitor APG-2449 Synergizes with Osimertinib in Preclinical Xenograft Models of EGFR-mutant NSCLC Session Title: Tyrosine Kinase and Phosphatase Inhibitors 2 Session Date and Time: Monday, April 1 2019 1:00 PM – 5:00 PM CDT Poster Number: 2204 About Ascentage Pharma Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. The Company’s expertise is in developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. Ascentage has built a rich pipeline of eight clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. For more information, please visit www.ascentagepharma.com.

The release as fetched from its publisher. ascentage.com ↗